ALLMedicine™ Gastrointestinal Tumors Center
Research & Reviews 266 results
https://clinicaltrials.gov/ct2/show/NCT00044304
May 13th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...
https://doi.org/10.1007/s00464-022-09266-y 10.1586/17474124.2014.902305 10.1007/s10620-013-2560-x 10.5009/gnl.2013.7.3.263 10.5009/gnl19266 10.1111/j.1443-1661.2010.00992.x 10.1016/j.gie.2010.08.041 10.1016/j.gie.2014.01.050 10.1055/s-0030-1255923 10.1016/j.gastrohep.2020.08.016 10.3748/wjg.v25.i10.1259 10.1159/000445957 10.1016/j.gie.2008.12.245 10.1007/s00464-016-5326-7 10.1111/j.1443-1661.2012.01264.x 10.1055/s-0042-112973 10.1055/s-0034-1391952 10.1016/j.gie.2008.03.1126 10.1155/2019/1083053 10.1055/s-0043-124866 10.1007/s00464-015-4580-4
Surgical Endoscopy; Zhang A, Song Y et. al.
May 6th, 2022 - Endoscopic submucosal dissection (ESD) is the treatment of choice for colorectal neoplasms in Japan. ESD can completely peel off the lesion and is associated with a significantly lower recurrence rate of colorectal cancers than EMR and is widely u...
https://clinicaltrials.gov/ct2/show/NCT03820310
Apr 26th, 2022 - Intrahepatic cholangiocarcinoma (ICC) accounts for 2%~3% of gastrointestinal tumors, and the incidence has been on the rise globally. The pathogenesis of ICC remains unclearly. Compared with palliative resection, the postoperative survival rate of...
https://doi.org/10.2174/1568009622666220407111013
Current Cancer Drug Targets; Yang T, Jia L et. al.
Apr 9th, 2022 - Explore the specific mechanism of TROP2 in promoting cancer in gastric cancer, and provide a basis for the prevention and treatment of gastric cancer. Background Gastric cancer (GC) is the fourth most commonly found cancer and the second highest c...
https://doi.org/10.1016/j.prp.2022.153843
Pathology, Research and Practice; Liu Z, Ma L et. al.
Mar 25th, 2022 - Increasing evidences demonstrated that long non-coding RNAs (lncRNAs) participates in the occurrence and development of cancer. In this study, we explored the function and molecular mechanism of LINC01123 in colorectal cancer progression. Analyze ...
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977951
World Journal of Gastroenterology; Marc G, Lopes CV
Aug 14th, 2008 - Therapeutic endoscopy plays a major role in the management of gastrointestinal (GI) neoplasia. Its indications can be generalized into four broad categories; to remove or obliterate neoplastic lesion, to palliate malignant obstruction, or to treat...
Drugs 5 results see all →
Clinicaltrials.gov 19 results
https://clinicaltrials.gov/ct2/show/NCT00044304
May 13th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...
https://clinicaltrials.gov/ct2/show/NCT03820310
Apr 26th, 2022 - Intrahepatic cholangiocarcinoma (ICC) accounts for 2%~3% of gastrointestinal tumors, and the incidence has been on the rise globally. The pathogenesis of ICC remains unclearly. Compared with palliative resection, the postoperative survival rate of...
https://clinicaltrials.gov/ct2/show/NCT05182983
Jan 10th, 2022 - The tongue images of patients with gastrointestinal diseases and healthy people will be collected and the tongue image database will be established. Through deep learning and artificial intelligence, early screening models of various gastrointesti...
https://clinicaltrials.gov/ct2/show/NCT04883970
Jun 4th, 2021 - The objective of the study is to constrcut a noninvasive approach 124I-18B10(10L) PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from CLDN18.2 targeting treatm...
https://clinicaltrials.gov/ct2/show/NCT04612712
Mar 29th, 2021 - The study consists of dose escalation and dose expansion. The preset dose of Donafenib is 50 mg BID, 100 mg BID and 200 mg BID, and the preset dose of KN046 is 5 mg/kg Q3W. Dose expansion will enroll subjects who with advanced hepatocellular carci...
News 21 results
https://www.onclive.com/view/average-cumulative-relative-adjuvant-chemo-dose-linked-with-survival-in-crc
Aug 17th, 2021 - Average cumulative relative dose (ACRD) was found to be associated with survival over average relative dose intensity (ARDI) in patients with colorectal cancer (CRC), highlighting that obese patients receive lower cumulative doses of adjuvant chem...
https://www.onclive.com/view/optimal-approach-toward-advanced-gastric-cancers-in-us
Apr 2nd, 2021 - Johanna Bendell, MD: In Japan, there are screening protocols that catch these cancers early so they can be cured before they get to an advanced setting. Here in the United States, we don’t have that so much. How are we trying to work to look at ea...
https://www.onclive.com/view/the-evolving-story-of-mutational-landscape-in-cancer-and-its-implications-bad-luck-or-great-hope
Dec 20th, 2020 - Andre Goy, MD Editor-in-Chief of Oncology & Biotech News Chairman and Director Chief of Lymphoma Director, Clinical and Translational Cancer Research John Theurer Cancer Center at Hackensack University Medical Center While it is...
https://www.onclive.com/view/survival-benefit-observed-with-cetuximab--in-ras-wild-type-colorectal-cancer
Dec 20th, 2020 - Volker Heinemann, MD, PhD Cetuximab (Erbitux) plus FOLFIRI may offer a survival advantage over FOLFIRI plus bevacizumab (Avastin) in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer who do not have RAS mu...
https://www.onclive.com/view/regorafenib-extends-pfs-in-locally-advanced-biliary-tract-cancer
Dec 20th, 2020 - The oral multi-kinase inhibitor regorafenib extended progression-free survival (PFS) in patients with metastatic or unresectable biliary tract cancer (BTC) who were previously treated with gemcitabine (Gemzar) and a platinum-based chemotherapy, ac...
